Newsroom

Absci 3d ago

Meet us in Barcelona for the Third #BCNHairMeeting! Prof. Ralf Paus MD, DSc, FRSB will present new findings on ABS-201, a novel AI-designed monoclonal antibody in a Phase 1/2a clinical trial. Title: "ABS-201-Mediated Prolactin Receptor Inhibition Promotes Hair Growth in Androgen-Sensitive Male Scalp Skin by Prolonging Anagen, Stimulating Hair Shaft Production, and Activating Stem Cells" 🗓️When: Saturday, September 19, 2026 | 10:35 CEST 📍Where: Room Llevant 1

View post on LinkedIn

Absci 1w ago

Absci offers AI Scientists a unique opportunity to both develop novel, cutting edge machine learning models and apply these models to identify novel targets, disease interventions and antibody therapeutic candidates. If you’re ready to push the boundaries of what’s possible in AI and biotech, we want to hear from you. Join Absci and build antibodies: 🔸Senior/Staff AI Scientist – Antibody Design – https://lnkd.in/gvGApunc 🔸 Senior/Staff AI Scientist – Target Discovery – https://lnkd.in/gHzNSE2n

View post on LinkedIn

Absci 2w ago

"The traditional model in our industry has been: win the HCP, then reach the patient. I think that's changing. Not because physicians stop mattering (they absolutely matter) but because the patient can now be at the center of the conversation about their own health, as they should have been all along."

View post on LinkedIn